



Cornerstone Pharmaceuticals, Inc.
1 Duncan Drive
Cranbury, New Jersey 08512-3629

Media Contact: Sanjeev Luther
Cornerstone Pharmaceuticals, Inc.
(609) 409-7050 ext. 201
Sanjeev@Cornerstonepharma.com

Cornerstone Pharmaceuticals Announces Acceptance of Abstract on CPI-613 Pancreatic Cancer Trial by European Society for Medical Oncology (ESMO) Congress 2016

CRANBURY, NEW JERSEY (October 06, 2016) – Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that European Society for Medical Oncology (ESMO) Congress 2016 has accepted the abstract on CPI-613 phase I trial for patients with first-line metastatic pancreatic cancer.

A copy of the abstract can be accessed under Science / Abstract section of the company's website at www.cornerstonepharma.com.

About CPI-613

CPI-613 is the lead drug candidate from Cornerstone's proprietary AEMD platform. Cornerstone's AEMD drug platform disrupts the essential "bioenergetic" differences that support the growth and development of many types of cancer cells. In the case of CPI-613, the compound has been shown to selectively induce inhibition of pyruvate dehydrogenase (PDH) and alpha ketoglutarate dehydrogenase (KGDH), key mitochondrial enzymes involved in cancer cell metabolism in vitro. Disruption of PDH and KGDH function cuts off the tumor's energy supply, culminating in cell death. CPI-613 is currently being evaluated in Phase I, I/II, and II human clinical trials in solid tumors and hematological malignancies.

About Cornerstone Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc. is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. The company's unique approach to targeting cancer metabolism has led to two distinct technology platforms: altered energy metabolism directed, or AEMD, compounds and an Emulsiphan lipid nanoemulsion based drug delivery system. www.cornerstonepharma.com.



###

This release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.